Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Publication
, Journal Article
Kleinstein, SE; Shea, PR; Stamm, LM; Sulkowski, M; Goldstein, DB; Naggie, S
Published in: Clin Infect Dis
June 1, 2018
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
June 1, 2018
Volume
66
Issue
12
Start / End Page
1953 / 1956
Location
United States
Related Subject Headings
- Sofosbuvir
- Recurrence
- Polymorphism, Single Nucleotide
- Microbiology
- Male
- Humans
- Hepatitis C
- Hepacivirus
- HIV Infections
- Genotype
Citation
APA
Chicago
ICMJE
MLA
NLM
Kleinstein, S. E., Shea, P. R., Stamm, L. M., Sulkowski, M., Goldstein, D. B., & Naggie, S. (2018). Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. Clin Infect Dis, 66(12), 1953–1956. https://doi.org/10.1093/cid/cix1051
Kleinstein, Sarah E., Patrick R. Shea, Luisa M. Stamm, Mark Sulkowski, David B. Goldstein, and Susanna Naggie. “Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.” Clin Infect Dis 66, no. 12 (June 1, 2018): 1953–56. https://doi.org/10.1093/cid/cix1051.
Kleinstein SE, Shea PR, Stamm LM, Sulkowski M, Goldstein DB, Naggie S. Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. Clin Infect Dis. 2018 Jun 1;66(12):1953–6.
Kleinstein, Sarah E., et al. “Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.” Clin Infect Dis, vol. 66, no. 12, June 2018, pp. 1953–56. Pubmed, doi:10.1093/cid/cix1051.
Kleinstein SE, Shea PR, Stamm LM, Sulkowski M, Goldstein DB, Naggie S. Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. Clin Infect Dis. 2018 Jun 1;66(12):1953–1956.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
June 1, 2018
Volume
66
Issue
12
Start / End Page
1953 / 1956
Location
United States
Related Subject Headings
- Sofosbuvir
- Recurrence
- Polymorphism, Single Nucleotide
- Microbiology
- Male
- Humans
- Hepatitis C
- Hepacivirus
- HIV Infections
- Genotype